We hypothesized that lower levels of inflammatory cytokine in vivo improved activity of 2nd-GG CAR-T through correct the immune dysregulation and reduce tumor IFN signaling, which requires further detection of phenotypes and exhaustion markers of T cells to confirm. This evidence concerns the gene IFNA1 and neoplasm.